TFRC and cancer: In addition, the increased expression of TfR1 observed in malignant cells make this receptor an attractive target for antibody-mediated cancer therapy and a mouse/human chimeric IgG3 specific for human TfR1 (ch128.1, an antibody-avidin fusion protein) has developed, which shows antitumor activity against certain malignant B cells in vitro through TfR1 degradation and iron deprivation63.